This study showed that FXR inhibits cervical cancer by upregulating SHP, MDM2, and p53 via direct interaction with SHP through the LRH-1 binding site, induction of SHP-MDM2 complex formation, and suppression of p53 ubiquitination. Here, MDM2 is linked to cervical cancer.